Cangrelor Dosing, Administration, and Clinical Outcomes for Patients Undergoing Complex and High-Risk Percutaneous Coronary Interventions.
BACKGROUND Cangrelor reduces thrombotic events in patients undergoing percutaneous coronary intervention (PCI), with the advantage of rapid onset and offset. However, premature discontinuation may increase the risk of acute thrombosis for patients undergoing complex/high-risk PCI (CHIP). AIMS We evaluated the real-wo...